tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2015-2-13-20tumors-131Research ArticleФУНДАМЕНТАЛЬНАЯ ОНКОЛОГИЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАFUNDAMENTAL ONCOLOGY AND EXPERIMENTAL MEDICINEТиреоидный статус как прогностический маркер в онкологииThyroid status as a prognostic factor in oncologyГлушаковРуслан ИвановичGlushakovRuslan Ivanovich

к. м.н., доцент кафедры фармакологии;

помощник начальника клиники акушерства и гинекологии по лечебной работе, Санкт-Петербург

Ph.D.,  the department of obstetrics and gynecology

glushakovruslan@gmail.comВласьеваОльга ВалерьевнаVLAS’EVAOLGA

врач-онколог клиники акушерства и гинекологии, Санкт-Петербург

врач-онколог клиники акушерства и гинекологии, Санкт-Петербург

olgavlaseva@yandex.ruСоболевИван ВикторовичSOBOLEVIVAN

врач-онколог онкогинекологического отделения, Санкт-Петербург

врач-онколог онкогинекологического отделения , Санкт-Петербург

sobol548@inbox.ruПрошинСергей НиколаевичPROSHINSERGEJ

д. м.н., заведующий кафедрой фармакологии, Санкт-Петербург

д. м.н., заведующий кафедрой фармакологии, Санкт-Петербург

psnjsn@rambler.ruТапильскаяНаталья ИгоревнаTAPIL’SKAYANATALYA

д. м.н., профессор кафедры онкологии и кафедры акушерства и гинекологии, Санкт-Петербург

д. м.н., профессор кафедры онкологии и кафедры акушерства и гинекологии

tapnatalia@yandex.ruГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РФ; ФГБВОУ ВПО «Военно-медицинская академия им. С. М. Кирова» МО РФРоссияS. M. Kirov Military Medical AcademyRussian FederationФГБВОУ ВПО «Военно-медицинская академия им. С. М. Кирова» МО РФРоссияФГБВОУ ВПО «Военно-медицинская академия им. С. М. Кирова» МО РФ,Russian FederationГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»РоссияГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»Russian FederationГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РФРоссияГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РФRussian FederationГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава РФРоссияГБОУ ВПО «Санкт-ПетербургсRussian Federation201501072015021320Copyright © Глушаков Р.И., Власьева О.В., Соболев И.В., Прошин С.Н., Тапильская Н.И., 20152015Глушаков Р.И., Власьева О.В., Соболев И.В., Прошин С.Н., Тапильская Н.И.Glushakov R.I., VLAS’EVA O., SOBOLEV I., PROSHIN S., TAPIL’SKAYA N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/131

В обзоре представлены данные о негеномных свойствах тиреоидных гормонов (ТГ), начало которым дают внеклеточные домены белка клеточной адгезии – интегрина V 3, в результате чего происходит активация митоген-активируемой протеин-киназы, фосфотидил-инозитол-3-киназы. Конечными эффектами негеномного действия являются активация клеточной пролиферации, ангиогенеза и миграции клеток, а также повышение экспрессии тканеспецифичных генов воспаления. Также приведены данные влияния клинических исследований, в которых прослежено увеличение ответа на лечение и увеличение выживаемости у онкологических больных с индуцированным гипотиреозом.

Acting via a cell surface receptor on integrin v 3, thyroid hormone is pro-angiogenic and pro-proliferating. Nongenomic mechanisms of actions of the thyroid hormones at v 3 include modulation of activities of intracellular messengers: mitogen-activated protein kinase and phosphatidyl inositol-3-kinase. Thyroid hormone may increase activity of factors that support neovascularization, cell motility and cell proliferation. There are clinical and epidemiological dates about impact induced hypothyroidism on the disease and survival in cancer patients in this review

негеномные эффекты тиреоидных гормоновиндуцированный гипотиреозnongenomic actions of the thyroid hormonesinduced hypothyroidismгрант Правительства Санкт-ПетербургаReferencesAghajanova L., Lindeberg M., Carlson I. B. et al. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue // Reprod. Biomed. Online. 2009; 18 (3): 337–347.Aghajanova L., Lindeberg M., Carlson I. B. et al. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue // Reprod. Biomed. Online. 2009; 18 (3): 337–347.Ashur-Fabian O., Blumenthal D. T., Bakon M. et al. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature // Anticancer Drugs. 2013; 24 (3): 315–23.Ashur-Fabian O., Blumenthal D. T., Bakon M. et al. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature // Anticancer Drugs. 2013; 24 (3): 315–23.Balkwill F., Charles K. A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease // Cancer Cell. 2005; 7: 211–217.Balkwill F., Charles K. A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease // Cancer Cell. 2005; 7: 211–217.Billon N., Terrinoni A., Jolicoeur C. et al. Roles for p53 and p73 during oligodendrocyte development // Development. 2004; 131: 1211–20.Billon N., Terrinoni A., Jolicoeur C. et al. Roles for p53 and p73 during oligodendrocyte development // Development. 2004; 131: 1211–20.Brown R. L. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management // Target Oncol. 2011; 6 (4): 217–26.Brown R. L. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management // Target Oncol. 2011; 6 (4): 217–26.Cao X., Kambe F., Moeller L. C. et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts // Mol. Endocrinol. 2005; 19 (1):102–112.Cao X., Kambe F., Moeller L. C. et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts // Mol. Endocrinol. 2005; 19 (1):Carvalho A. F., Dimellis D., Gonda X. et al. Rapid cycling in bipolar disorder: a systematic review // J Clin Psychiatry. 2014; 75 (6): e578–86.102–112.Cohen K., Ellis M., Khoury S. et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via v 3 integrin // Mol. Cancer Res. 2011; 9 (10): 1385–94.Carvalho A. F., Dimellis D., Gonda X. et al. Rapid cycling in bipolar disorder: a systematic review // J Clin Psychiatry. 2014; 75 (6): e578–86.Crile G. Jr. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth // Cancer. 1957; 10 (6): 1119–37.Cohen K., Ellis M., Khoury S. et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via v 3 integrin // Mol. Cancer Res. 2011; 9 (10): 1385–94.Davis F. B., Tang H. Y., Shih A. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells // Cancer Res. 2006; 66 (14): 7270–7275.Crile G. Jr. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth // Cancer. 1957; 10 (6): 1119–37.Davis F. B., Mousa S. A., O’Connor L. et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface // Circ. Res. 2004; 94 (11): 1500–1506.Davis F. B., Tang H. Y., Shih A. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells // Cancer Res. 2006; 66 (14): 7270–7275.Davis P. J., Lin H. Y., Tang H. Y. et al. Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone // Thyroid. 2013; 23 (12): 1503–9.Davis F. B., Mousa S. A., O’Connor L. et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface // Circ. Res. 2004; 94 (11): 1500–1506.Demartini B., Ranieri R., Masu A. et al. Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study // J Nerv Ment Dis. 2014; 202 (8): 603–7.Davis P. J., Lin H. Y., Tang H. Y. et al. Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone // Thyroid. 2013; 23 (12): 1503–9.Faber J, Selmer C. Cardiovascular disease and thyroid function // Front Horm Res. 2014; 43: 45–56.Demartini B., Ranieri R., Masu A. et al. Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study // J Nerv Ment Dis. 2014; 202 (8): 603–7.Farwell A. P., Dubord–Tomasetti S.A., Pietrzykowski A. Z., Leonard J. L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3»,5’-triiodothyronine // Brain Res. Dev. Brain Res. 2005; 154 (11): 121–135.Faber J, Selmer C. Cardiovascular disease and thyroid function // Front Horm Res. 2014; 43: 45–56.Hercbergs A. A., Suh J. H., Lee S. et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study // Anticancer Res. 2003; 23 (1B): 617–626.Farwell A. P., Dubord–Tomasetti S.A., Pietrzykowski A. Z., Leonard J. L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3»,5’-triiodothyronine // Brain Res. Dev. Brain Res. 2005; 154 (11): 121–135.Huang S. A. Physiology and pathophysiology of type 3 deiodinase in humans // Thyroid. – 2005; 15 (8): 875–881.Hercbergs A. A., Suh J. H., Lee S. et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study // Anticancer Res. 2003; 23 (1B): 617–626.Humphrey L. J., Swerdlow M. The relationship of breast disease to thyroid disease // Cancer. 1964; 17: 1170–3.Huang S. A. Physiology and pathophysiology of type 3 deiodinase in humans // Thyroid. – 2005; 15 (8): 875–881.Linetsky E., Hercbergs A. A., Dotan S. et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas // Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology: Edinburgh, U.K. 2005: 318.Humphrey L. J., Swerdlow M. The relationship of breast disease to thyroid disease // Cancer. 1964; 17: 1170–3.Lodish M. B., Stratakis C. A. Endocrine side effects of broad-acting kinase inhibitors // Endocr Relat Cancer. 2010; 17 (3): R233–44.Linetsky E., Hercbergs A. A., Dotan S. et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas // Abstracts from the World Federation ofMoeller L. C., Dumitrescu A. M., Walker R. L. et al. Thyroid hormone responsive genes in cultured human fibroblasts // J. Clin. Endocrinol. Metab. 2005: 90 (2): 936–943.Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology: Edinburgh, U.K. 2005: 318.Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer // Arch Otolaryngol Head Neck Surg. 2006; 132 (10): 1041–6.Lodish M. B., Stratakis C. A. Endocrine side effects of broad-acting kinase inhibitors // Endocr Relat Cancer. 2010; 17 (3): R233–44.Rae M. T., Gubbay O., Kostogiannou A. et al. Thyroid hormone signaling in human ovarian surface epithelial cells // J. Clin. Endocrinol. Metab. 2007.; 92 (1): 322–327.Moeller L. C., Dumitrescu A. M., Walker R. L. et al. Thyroid hormone responsive genes in cultured human fibroblasts // J. Clin. Endocrinol. Metab. 2005: 90 (2): 936–943.Reid I., Sharpe I., McDevitt J. et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha // Br J Cancer. 1991; 64 (5): 915–8.Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer // Arch Otolaryngol Head Neck Surg. 2006; 132 (10): 1041–6.Riesenbeck L. M., Bierer S., Hoffmeister I. et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib // World J Urol. 2011; 29 (6): 807–13.Rae M. T., Gubbay O., Kostogiannou A. et al. Thyroid hormone signaling in human ovarian surface epithelial cells // J. Clin. Endocrinol. Metab. 2007.; 92 (1): 322–327.Russfield A. B. Histology of the human hypophysis in thyroid disease-hypothyroidism, hyperthyroidism, and cancer // J Clin Endocrinol Metab. 1955; 15 (11): 1393–408.Reid I., Sharpe I., McDevitt J. et al. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha // Br J Cancer. 1991; 64 (5): 915–8.Sabatier R., Eymard J. C., Walz J. et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? // Ann Oncol. 2012; 23 (3): 714–21.Riesenbeck L. M., Bierer S., Hoffmeister I. et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib // World J Urol. 2011; 29 (6): 807–13.Schmidinger M., Vogl U. M., Bojic M. et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? // Cancer. 2011; 117 (3): 534–44.Russfield A. B. Histology of the human hypophysis in thyroid disease-hypothyroidism, hyperthyroidism, and cancer // J Clin Endocrinol Metab. 1955; 15 (11): 1393–408.Schwartz M. A. Integrin signaling revisited // Trends Cell Biol. 2001; 11: 466–470.Sabatier R., Eymard J. C., Walz J. et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? // Ann Oncol. 2012; 23 (3): 714–21.Shih C., Chen S., Yen C. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins // Endocrinology. 2004; 145: 2804–2814.Schmidinger M., Vogl U. M., Bojic M. et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? // Cancer. 2011; 117 (3): 534–44.Siegrist-Kaiser C.A., Juge-Aubry C., Tranter M. P. et al. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone // J. Biol. Chem. 1990; 265: 5296–5302.Schwartz M. A. Integrin signaling revisited // Trends Cell Biol. 2001; 11: 466– 470.Smith T. G., Roblins P. A., Ratelife P. J. The human side of hypoxia-inducible factor // Brit. J. Haemot. 2008; 141: 325–334.Shih C., Chen S., Yen C. et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins // Endocrinology. 2004; 145: 2804–2814.Tang H. Y., Lin H. Y., Zhang S. et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor // Endocrinology. 2004; 145: 3265–3272.Siegrist-Kaiser C.A., Juge-Aubry C., Tranter M. P. et al. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone // J. Biol. Chem. 1990; 265: 5296–5302.Viguerie N., Millet L., Avizou S. et al. Regulation of human adipocyte gene expression by thyroid hormone // J. Clin. Endocrinol. Metab. 2002; 87: 630–634.Smith T. G., Roblins P. A., Ratelife P. J. The human side of hypoxia-inducible factor // Brit. J. Haemot. 2008; 141: 325–334.Wang X., Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation // J Cell Biol. 2014; 206 (7): 923–36.Tang H. Y., Lin H. Y., Zhang S. et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor // Endocrinology. 2004; 145: 3265–3272.Weijl N. I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment // J Clin Oncol. 1993; 11 (7): 1376–83.Viguerie N., Millet L., Avizou S. et al. Regulation of human adipocyte gene expression by thyroid hormone // J. Clin. Endocrinol. Metab. 2002; 87: 630–634.Wolter P., Stefan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) // ASCO Meeting Abstracts 5126, 2008.Wang X., Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation // J Cell Biol. 2014; 206 (7): 923–36.Weijl N. I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment // J Clin Oncol. 1993; 11 (7): 1376–83.Weijl N. I., Van der Harst D., Brand A. et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment // J Clin Oncol. 1993; 11 (7): 1376–83.Wolter P., Stefan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) // ASCO Meeting Abstracts 5126, 2008.Wolter P., Stefan C., Decallonne B. et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC) // ASCO Meeting Abstracts 5126, 2008.

The authors declare that there are no conflicts of interest present.